Robot
29.Mar.25 4:21 AM

Crypto Market Plunges as Inflation Fears Resurface, Bitcoin Price Tumbles Below $85,000

The cryptocurrency market experienced a significant drop on Friday, fueled by renewed inflation fears and liquidations of nearly $444 million. Bitcoin's price tumbled below $85,000, raising questions about the continuation of the bull run, with analysts divided on the direction of future price movements.
Robot
29.Mar.25 4:16 AM

Monetization and Growth Potential Drive Analyst's Buy Rating and $100 Price Target

JP Morgan analyst Brent Navon maintains a Buy rating on Roku (ROKU) with a $100 price target, citing the company's strong position in the streaming market and its potential for monetization growth. Navon believes Roku's scale, user base, and favorable industry trends will drive significant revenue and profitability gains in the coming years.
Robot
29.Mar.25 4:04 AM

Javice Convicted for JPMorgan Chase Fraud, LaForte Sentenced for Investment Scheme

Charlie Javice, founder of student finance startup Frank, was convicted of defrauding JPMorgan Chase in its $175 million acquisition of the company by inflating Frank's customer base through falsified user data. Meanwhile, Philadelphia businessman Joseph LaForte received a 15-and-a-half-year prison sentence for orchestrating a $404 million investment fraud scheme through Par Funding while evading millions in taxes.
Robot
29.Mar.25 3:54 AM

Trump's Auto Tariffs Spark Market Turmoil, Fueling Inflation Fears and Consumer Unease

President Trump's announcement of sweeping tariffs on imported automobiles sent shockwaves through the market, pushing vehicle prices higher and dragging down broader sectors amid fears of escalating trade tensions. This policy shift also fueled inflation concerns, with the Fed's preferred inflation gauge exceeding expectations and consumer inflation expectations reaching their highest level since 1993.
Robot
29.Mar.25 3:50 AM

Pluvicto Approved for More Prostate Cancer Patients

The FDA has approved Novartis' Pluvicto for a broader range of prostate cancer patients, significantly increasing the number of eligible patients. This approval is based on the Phase 3 PSMAfore trial, which demonstrated Pluvicto's efficacy and favorable safety profile in patients with PSMA-positive mCRPC who had previously received ARPI therapy.